Vodafone dialled up by TD clients

Stuart Welch, CEO, TD Direct Investing comments: "TD clients this week were interested in Vodafone (VOD), after the company reported a substantial drop in revenues for the first six months of the 2012 fiscal year. The mobile communications company topped the buys for TD clients and landed seventh place in sells, with a buy:sell ratio of 10.4:1. Over the week, trades in Vodafone accounted for 23.5% of the top ten TD client trades and the share price dropped from opening at 160.8p on Tuesday 13 November to close at 160.15p on Monday, 19 November. Meanwhile, the FTSE 100 finished 29.61 points lower than the previous week, closing Monday at 5,737.66.

"GlaxoSmithKline (GSK) featured in seventh place in the buys this week, after the pharmaceutical giant agreed to extend its strategic partnership with Aptuit Inc., which carries out drug discovery and development in Verona. Also last week, the U.S. Food and Drug Administration approved the use of GlaxoSmithKline's PROMACTA drug in patients with chronic hepatitis C. TD clients seemed to take the opportunity to buy the shares, which opened at 1353p on Tuesday, 13 November and closed at 1326.26p on Monday, 19 November.

"BG Group (BG.) stayed in the top ten buys this week, occupying fourth place, after the natural gas and oil company agreed to sell its stake in Argentine natural gas distributor Metrogas (PINK:MGSBF). Over the week, the share price fell 39.5p, from opening at 1040.5p on Tuesday 13 November to close at 1001p on Monday 19 November."

The value of your investments can go down as well as up. You may not get back all the funds that you invest.

For more information clients can log on to tddirectinvesting.co.uk.